As earnings season marches along, it's becoming increasingly clear that there's only one thing that scares big drug companies, and that's losing pricing power to other actors in the healthcare market.
Based on what we're seeing, some of that power is already slipping away. And mostly the drug companies are scared they're losing it to PBMs, pharmacy benefit managers.
Netflix has traditionally been a pretty cheap form of entertainment, but the company has spent the last several years beefing up its originals lineup and prices increases have happened thanks to the big budgetary changes.
Third quarter earnings have begun to come in, and an end to the five-quarter earnings recession for companies in the S&P 500 isn't likely. Investors have continued to bid up stocks on the
Almost a year after pharmaceutical price hikes became the focus of national attention with the 5,000% overnight increase of the drug Daraprim, pricing remains a big issue in the US. In August, Mylan, the company that makes the EpiPe...
As challenges in the American home healthcare markets come more into focus, smart operators will begin to realize that to retain their investors’ interest and appetite to fund growth, targeting markets such as China and India will b...